A Phase 3 Randomized, Placebo-Controlled, Double-Blind Study to Evaluate Upadacitinib in Combination with Topical Corticosteroids in Adolescent and Adult Subjects with Moderate to Severe Atopic Dermatitis
Primary Objective is to evaluate the clinical efficacy of oral apremilast 30 mg twice daily (BID), compared to placebo, in subjects with moderate to severe genital psoriasis during the 16-week Placebo-controlled Phase.
Available at the following location(s)
Do you need help with some of the labels on this page?
Read our glossary of terms